Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Categories (click each to see list of all clinical trials associated with that category): Brain/Neuro, Gastrointestinal (GI), Genitourinary (GU), Leukemia/Myelodysplastic syndromes (MDS)/Myeloproliferative disorders (MPD), Lung/Thoracic, Lymphoma/Chronic lymphocytic leukemia (CLL), Myeloma/Plasma Cell Dyscrasia , Sarcoma
Current Status: Open to accrual
Principal Investigator: Marr, Alissa
Brandie Booker, RN
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.